title: Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics.
abstract: BACKGROUND
  Medical registries can be used to assess and monitor the effectiveness and safety of approved therapy, and provide insights into how quality of care can be optimized.
  
  
  METHODS
  The post-marketing, non-interventional, observational registry (eXpeRience) aims to collect data on the treatment effectiveness and safety of omalizumab in 'real-world' practice. The baseline characteristics of patients with uncontrolled allergic asthma receiving omalizumab therapy and included in the first interim analysis of this observational registry are reported.
  
  
  RESULTS
  A total of 294 patients were included in the first interim analysis. Of these patients, 271 (92.2%) were active in the registry at the time of reporting. At baseline, the mean duration of allergic asthma was approximately 19 years, with over 87% of patients testing positive for a perennial allergen. Mean % predicted FEV(1) and serum total IgE levels were 62.4% and 316.7 IU/mL, respectively. Asthma was uncontrolled for approximately 62% of patients, while around 23% were partly controlled. The majority of patients were being treated with multiple asthma controller medications, including inhaled-corticosteroids, long-acting β(2)-agonists and leukotriene receptor antagonists, and 28% of patients were also receiving maintenance oral corticosteroids. Concomitant diseases were present in many patients, the most common being perennial allergic rhinitis (42.5%).
  
  
  CONCLUSIONS
  Demographic and disease characteristics highlight the unmet clinical need in patients with uncontrolled allergic asthma. Future analyses from this study will further determine the real-life effectiveness and safety of omalizumab.
authors.affiliation: Department of Pulmonary Medicine, St. Franciscus Gasthuis, Rotterdam, The Netherlands. g.braunstahl@sfg.nl
authors.forename: Gert-Jan
authors.initials: GJ
authors.lastname: Braunstahl
authors.forename: Jo
authors.initials: J
authors.lastname: Leo
authors.forename: Jackie
authors.initials: J
authors.lastname: Thirlwell
authors.forename: Guy
authors.initials: G
authors.lastname: Peachey
authors.forename: Robert
authors.initials: R
authors.lastname: Maykut
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D002648:Child; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011364:Professional Practice / Q000706:statistics & numerical data*; D011788:Quality of Life; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab